Pasar al contenido principal

Marta Martínez Vicente

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

Marta Martínez Vicente

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Neurodegenerativas
Vall Hebron Institut de Recerca

I am senior researcher at the VHIR, I’m a Principal Investigator at the Neurodegenerative Diseases Group and I head the Autophagy and Lysosomal Dysfunction lab.

I obtained a degree in Chemistry/Biochemistry and a PhD in Biochemistry by the University of Valencia. From 2004 to 2008, I worked as a postdoctoral researcher at the laboratory of Dr. Ana Maria Cuervo at the Albert Einstein College of Medicine (New York, USA), focusing on the role of autophagy in neurodegenerative diseases and aging.
I obtained in 2010 a tenure-track position as Miguel Servet I in the Neurodegenerative Diseases Group of the VHIR and since January 2016 I became VHIR Senior Researcher (Miguel Servet II-A).
Currently, the efforts of my team are devoted to study the role of autophagy in neurodegeneration. Alterations in the autophagy process have been associated with neurodegenerative diseases including Parkinson’s, Huntington’s and Alzheimer’s disease and has been shown to be one of the main causes that contribute to neuronal death in these pathologies. Our efforts are currently directed to: 1) Study the role of the autophagic and lysosomal dysfunction in Parkinson’s disease; 2) Development of new therapies for Parkinson’s disease based in the restoration of lysosomal glucocerebrosidase (GBA) activity; 4) Unravel the link between Parkinson and lysosomal storage diseases, 4) Characterize the defective lysosomal-mediated turnover of mitochondria and aggregates in Huntington’s disease and its contribution to neurodegeneration.
I’ve been able to turn my group into a reference group in the study of autophagy in neurodegeneration and aging. This position is endorsed by our publications, projects, dissemination activities and participation in scientific organizations. Bibliographic parameters: h-index: 31. Citations: >12.000, Publications: 49 scientific articles and mean impact factor/publication in the last 6 years = 10.6. I’ve been PI of several research projects funded by public agencies like ISCIII and MINECO as well as private entities as the Michael J. Fox Foundation, the Silverstein foundation and the BBVA Foundation, in addition I have also been PI in several collaboration agreements with private biotech companies.
I’m member of the Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), member and part of the management committee (board member) of the Spanish Autophagy Network (SEAFAGIA), member and part of the management committee of the European COST TRANSAUTOPHGAY network, member and part of the Scientific Advice Committee of the Women in Autophagy (WIA), member of the Spanish Society of Biochemistry and Molecular Biology (SEBBEM), and member of the Association of Women Researcher and Technologists (AMIT). As member of theses scientific societies I participated in the organization of national and international scientific conferences and I am member of the Editorial Board of Cells (ISSN 2073-440). I am in possession of the accreditation of Associate Professor/Researcher by the Agència per a Qualitat del Sistema Universitari de Catalunya (AQU).

Proyectos

Therapeutic target of GCase enzyme in Parkinson's disease with novel pharmacological chaperones

IP: Marta Martínez Vicente
Colaboradores: Marta Montpeyó Garcia-Moreno
Entidad financiadora: Michael J. Fox Foundation
Financiación: 263858.59
Referencia: GCASE_MJFF-SILVERSTEIN2018
Duración: 14/12/2018 - 31/12/2021

Caracterització genètica i desenvolupament de noves estratègies traslacionals en la malatia de Parkinson

IP: Marta Martínez Vicente
Colaboradores: Jordi Riera Heredia, Laia Perez Lasarte
Entidad financiadora: Generalitat de Catalunya - Departament de Salut
Financiación: 67280.97
Referencia: SLT006/17/00268
Duración: 12/03/2018 - 31/12/2020

La disfunción autofágica/lisosomal en la enfermedad de Parkinson: caracterización y desarrollo de nuevas estrategias traslacionales con el lisosoma como diana terapéutica

IP: Marta Martínez Vicente
Colaboradores: Jorge Hernández Vara, Oriol de Fabregues-Boixar Nebot, Thais Cuadros Arasa, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Manuel Quintana Luque
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 99220
Referencia: PI17/00496
Duración: 01/01/2018 - 30/06/2021

Estudio del rol patogénico de la disfunción autofágica en la enfermedad de Parkinson asociada a mutaciones en GBA. Desarrollo de nuevos fármacos moduladores de la autofagia como nueva estrategia terapéutica en las enfermedades neurodegenerativas.

IP: Miquel Vila Bover
Colaboradores: Marta Martínez Vicente, Laia Perez Lasarte
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 101250
Referencia: CPII15/00007
Duración: 01/01/2016 - 31/12/2018

Noticias relacionadas

La III Jornada de Parkinson de Vall d’Hebron se ha centrado en la evolución durante los 40 años de la Unidad de Trastornos del Movimiento del hospital y en el testimonio cercano de pacientes con la enfermedad.

En el Día Mundial del Ensayo Clínico, destacamos algunos de los estudios donde hemos participado que han confirmado la eficacia de nuevos fármacos y han permitido su aprobación por las agencias reguladoras.

Vall d’Hebron ha participado en un ensayo clínico de fase III que confirma la eficacia y seguridad de la infusión subcutánea de una terapia con levodopa.

Profesionales relacionados

Teresa Casals Galobart

Teresa Casals Galobart

Investigador predoctoral
Leer más
Maria Belén Viñado Perez

Maria Belén Viñado Perez

Leer más
Jordi Selga Marsà

Jordi Selga Marsà

Cirugía Reconstructiva del Aparato Locomotor
Leer más
Montse Bach Oller

Montse Bach Oller

Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.